Authors
Craig A Magaret, Li Li, Allan C deCamp, Morgane Rolland, Michal Juraska, Brian D Williamson, James Ludwig, Cindy Molitor, David Benkeser, Alex Luedtke, Brian Simpkins, Fei Heng, Yanqing Sun, Lindsay N Carpp, Hongjun Bai, Bethany L Dearlove, Elena E Giorgi, Mandy Jongeneelen, Boerries Brandenburg, Matthew McCallum, John E Bowen, David Veesler, Jerald Sadoff, Glenda E Gray, Sanne Roels, An Vandebosch, Daniel J Stieh, Mathieu Le Gars, Johan Vingerhoets, Beatriz Grinsztejn, Paul A Goepfert, Leonardo Paiva de Sousa, Mayara Secco Torres Silva, Martin Casapia, Marcelo H Losso, Susan J Little, Aditya Gaur, Linda-Gail Bekker, Nigel Garrett, Carla Truyers, Ilse Van Dromme, Edith Swann, Mary A Marovich, Dean Follmann, Kathleen M Neuzil, Lawrence Corey, Alexander L Greninger, Pavitra Roychoudhury, Ollivier Hyrien, Peter B Gilbert
Publication date
2024/3/11
Journal
Nature Communications
Volume
15
Issue
1
Pages
2175
Publisher
Nature Publishing Group UK
Description
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p < 0.05]. VE differed by residue match vs. mismatch to the vaccine-insert at 16 amino acid positions (4 FWER p < 0.05; 12 q-value ≤ 0.20); significantly decreased with physicochemical-weighted Hamming distance to the vaccine-strain sequence for Spike, receptor-binding domain, N-terminal domain, and S1 (FWER p < 0.001); differed (FWER ≤ 0.05) by distance to the vaccine strain measured …
Scholar articles
CA Magaret, L Li, AC deCamp, M Rolland, M Juraska… - Nature Communications, 2024